Company Overview

Merck & Co., Inc. is a global healthcare company operating through two primary segments: Pharmaceutical and Animal Health. Known as Merck in the U.S. and Canada, and MSD elsewhere, it is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. For over 130 years, Merck has been dedicated to bringing hope to humanity through the development of impactful medicines and vaccines. The company aspires to be the premier research-intensive biopharmaceutical company globally, currently standing at the forefront of research to deliver innovative health solutions for the prevention and treatment of diseases in both people and animals.

Business Segments and Key Products

Merck operates through two main divisions:

Pharmaceutical Segment

This segment focuses on human health pharmaceutical products across various therapeutic areas. Key brands include:

- Oncology: Keytruda (pembrolizumab) - a leading cancer immunotherapy; Welireg.

- Vaccines: Gardasil/Gardasil 9 (HPV vaccines for cancer prevention), ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23.

- Cardiovascular/Metabolic: Januvia/Janumet (diabetes management), Adempas, Verquvo.

- Hospital Acute Care: Bridion, Dificid, Zerbaxa, Noxafil, Winrevair.

- Antivirals: Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro.

Flagship Products Highlighted:

- Keytruda (pembrolizumab): A cornerstone in cancer immunotherapy, dominating the oncology market.

- Gardasil/Gardasil 9: Essential HPV vaccines crucial for cancer prevention.

- Januvia/Janumet: Widely used medications for diabetes management.

- Winrevair: A treatment for pulmonary arterial hypertension.

Animal Health Division

This division provides a comprehensive range of veterinary pharmaceuticals, vaccines, and health management solutions. It caters to both livestock and companion animals.

- Livestock Products: Brands include Nuflor, Bovilis/Vista, Banamine, Revalor, Safe-Guard, Porcilis, Exzolt, and more.

- Livestock Intelligence: Allflex Livestock Intelligence solutions.

- Companion Animal Products: Brands such as Bravecto, Sentinel Spectrum, Optimmune, Mometamax, Caninsulin/Vetsulin, Panacur, and others.

Financial Performance & Market Position

Market Capitalization

As of Tuesday, September 16, 2025, Merck & Co. (MRK) held a market capitalization of $202.708 Billion. The company is recognized as a major player, ranking fourth among the largest biomedical companies by revenue and holding significant positions on lists like the Fortune 500 (65th) and Forbes Global 2000 (76th).

Recent Financial Results

Q1 2025 Performance:

- Total Worldwide Sales: $15.5 Billion (a decrease of 2% from Q1 2024; 1% growth excluding foreign exchange impact).

- Keytruda Sales: $7.2 Billion (up 4%; 6% growth excluding foreign exchange).

- Winrevair Sales: $280 Million.

- Animal Health Sales: $1.6 Billion (up 5%).

- Gardasil Sales: $1.3 Billion (down 41%).

Full-Year 2024 Results:

- Q4 Worldwide Sales: $15.6 Billion (an increase of 7% from Q4 2023).

- Full-Year 2024 Worldwide Sales: $64.2 Billion (an increase of 7% from full-year 2023).

Revenue Breakdown by Product (2024)

- Keytruda (pembrolizumab): Contributed 46% of revenue, amounting to $29.5 Billion.

- Gardasil (HPV vaccine): Contributed 13% of revenue, totaling $8.6 Billion.

- Animal Health Products: Contributed 9% of revenue, amounting to $5.8 Billion.

Strategic Developments & Pipeline

Recent Regulatory Approvals

- Vaccines: Received EC approval for CAPVAXIVE (pneumococcal disease prevention), marking its fourth global approval. GARDASIL 9 was approved for males in China, making it the first 9-valent HPV vaccine available for males in that region.

- HIV Treatment: Presented positive Phase 3 trial results for the investigational DOR/ISL (doravirine/islatravir) oral regimen for virologically suppressed HIV-1 adults, with marketing applications planned by mid-2025.

Research & Development Progress

Merck continues to invest heavily in R&D, with a robust pipeline focused on addressing unmet medical needs across oncology, vaccines, infectious diseases, and animal health. The positive results from the DOR/ISL trials are a significant step forward in HIV treatment innovation.

Future Outlook & Challenges

Merck anticipates potential sales declines in the late 2020s as patents for its core oncology drug, Keytruda, expire in the U.S. (expected around 2028). This patent cliff is a key concern, given Keytruda's substantial contribution to overall revenue. However, the company's strategy emphasizes pipeline launches to mitigate these declines, projecting a limited impact during the 2029-2030 period. Following a period of moderate R&D productivity, Merck's current drug development strategy is delivering important new therapies. The combination of a strong lineup of high-margin drugs and a promising pipeline is expected to ensure strong, long-term returns on invested capital.

Stock Trading Information

- Latest Closing Stock Price: $81.14 (as of September 17, 2025)

- 52-Week High: $119.20 (46.9% above current price)

- 52-Week Low: $73.31 (9.6% below current price)

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK". The company remains a significant and diversified force in the global pharmaceutical industry, with its portfolio spanning critical areas like oncology, vaccines, infectious diseases, and animal health.